| Year ended | Year ended | ||
| 31 December 2024 | 31 December 2023 | ||
| Note | £ 000 | £ 000 | |
| Continuing operations | |||
| Revenue | 3 | ||
| Cost of sales | ( | ( | |
| Gross loss | ( | ( | |
| Administrative expenses | 6 | ( | ( |
| Other operating income | 5 | ||
Operating loss from continuing operations before impairment charges and fair value adjustments | 3 | ( | ( |
| Fair value adjustments to investments | 27 | ( | ( |
| Impairment charges – intangible assets | 6 | ( | ( |
| Impairment charges – trade and other receivables | 14 | ( | |
| Operating loss from continuing operations | ( | ( | |
| Finance costs | 4 | ( | ( |
| Loss before tax from continuing operations | ( | ( | |
| Taxation | 10 | ||
| Loss after tax from continuing operations | ( | ( | |
| Discontinued operations | |||
| Loss from discontinued operations | 26 | ( | |
| Total loss for the year | ( | ( | |
| Other comprehensive income | |||
| Exchange differences on translating foreign operations | |||
| Total comprehensive loss for the year | ( | ( | |
| Loss attributable to: | |||
| Owners of the Company | ( | ( | |
| Earnings/(loss) per share | Pence | Pence | |
| Basic and diluted loss per share – continuing operations | 11 | ( | ( |
| Basic and diluted loss per share – discontinued operations | 11 | ( | |
| Basic and diluted loss per share – total | 11 | ( | ( |
| As at | As at | ||
| 31 December 2024 | 31 December 2023 | ||
| Note | £ 000 | £ 000 | |
| Non-current assets | |||
| Intangible assets and goodwill | 12 | ||
| Investment | 27 | ||
| Property, plant and equipment | |||
| Other non-current assets | |||
| Total non-current assets | |||
| Current assets | |||
| Trade and other receivables | 13 | | |
| Cash and cash equivalents | |||
| Receivable from related party | 14 | ||
| Total current assets | |||
| Total assets | |||
| Current liabilities | |||
| Trade and other payables | 16 | | |
| Total current liabilities | |||
| Net current liabilities | ( | ( | |
| Non-current liabilities | |||
| Long-term borrowings | 17 | | |
| Provisions | 18 | ||
| Deferred tax liabilities | |||
| Total non-current liabilities | |||
| Net liabilities | ( | ( | |
| Equity attributable to owners of the parent | |||
| Share capital | 15 | | |
| Share premium | |||
| Share-based payment reserve | 24 | ||
| Other reserves | ( | ( | |
| Retained losses | ( | ( | |
| Total equity | ( | ( |
| Share- | ||||||||||
| based | Reverse | Foreign | ||||||||
| Share | Share | Other | payment | Merger | takeover | currency | Retained | |||
| capital | premium | reserves* | reserve | reserve* | reserve* | reserve* | losses | Total | ||
| Note | £ 000 | £ 000 | £ 000 | £ 000 | £ 000 | £ 000 | £ 000 | £ 000 | £ 000 | |
| At 1 January 2023 | ( | ( | ( | ( | ||||||
| Loss for the year | ( | ( | ||||||||
| Foreign currency translation | ||||||||||
reserve reclassified to comprehensive income on disposal of 81% of TradeFlow | ||||||||||
| Forex retranslation difference | ||||||||||
| ( | ( | ( | ( | |||||||
| Issuance of new shares | 15 | |||||||||
| Costs incurred in connection | ||||||||||
| with the issuance of new | ||||||||||
| ordinary shares | ( | ( | ||||||||
Credit to equity for issue of warrants | 25 | |||||||||
| Exercise of Open Offer Warrants | 15 | ( | ||||||||
| Increase in fair value of previously | ||||||||||
| issued warrants | 25 | ( | ( | |||||||
| Equity settled employee share | ||||||||||
| based payment schemes | ||||||||||
| Pension plan actuarial gain or loss | ( | ( | ||||||||
| At 31 December 2023 | ( | ( | ( | ( |
| Share- | ||||||||||
| based | Reverse | Foreign | ||||||||
| Share | Share | Other | payment | Merger | takeover | currency | Retained | |||
| capital | premium | reserves* | reserve | reserve* | reserve* | reserve* | losses | Total | ||
| Note | £ 000 | £ 000 | £ 000 | £ 000 | £ 000 | £ 000 | £ 000 | £ 000 | £ 000 | |
| At | ( | ( | ( | ( | ||||||
| Loss for the year | ( | ( | ||||||||
| Forex retranslation difference | ||||||||||
| ( | ( | ( | ||||||||
| Issuance of new shares | 15 | |||||||||
Costs incurred in connection with the issuance of new ordinary | ||||||||||
| shares | ( | ( | ||||||||
Credit to equity for issue of warrants | 25 | |||||||||
| Exercise of Open Offer Warrants | | | ||||||||
| Equity settled employee share | ||||||||||
| based payment schemes | ||||||||||
| Pension plan actuarial gain or loss | | |||||||||
| At | ( | ( | ( |
| Year ended | Year ended | ||
| 31 December 2024 | 31 December 2023 | ||
| Note | £ 000 | £ 000 | |
| Cash flows from operating activities | |||
| Loss before interest and tax for the year from continuing operations | ( | ( | |
| Loss before interest and tax for the year from discontinued operations | ( | ||
| Total loss for the period before interest and tax | ( | ( | |
| Adjustment for impairment charge | |||
| Impairment charges – intangible assets | 6 | | |
| Impairment charges – trade and other receivables | 14 | | |
| Adjustments for fair value on investments | |||
| Fair value adjustments to investments | 27 | | |
| Adjustments for non-cash acquisition related costs | |||
| Amortisation of intangible assets arising on acquisition | 26 | ||
| Adjustments for non-cash costs related to the disposal of the discontinued operations | |||
| Foreign currency translation loss reclassified to comprehensive income | 26 | | |
| Profit on disposal of 81% of TradeFlow | 26 | | ( |
| | |||
| Other non-cash adjustments | |||
| Other depreciation and amortisation | |||
| Increase in provisions | |||
| Decrease in accrued income | |||
| (Increase)/decrease in trade and other receivables | ( | ||
| (Decrease) in trade and other payables | ( | ( | |
| Other (increases)/decreases in net working capital | ( | ||
| Net cash flows from operations | ( | ( | |
| Interest paid in cash | ( | ( | |
| Cash received from Research & Development Tax Credit under the UK SME tax | |||
| credit scheme | |||
| Net cash flow from operating activities | ( | ( |
| Year ended | Year ended | ||
| 31 December 2024 | 31 December 2023 | ||
| Note | £ 000 | £ 000 | |
| Cash flows from investing activities | |||
| Purchase of intangible assets | 12 | ( | ( |
| Other movements in non-current assets | |||
| Consideration received from related party on disposal of discontinued operations | |||
| Cash outflow on disposal of discontinued operations | 26 | | ( |
| Net cash flows from investing activities | |||
| Cash flows from financing activities | |||
| Net cash inflow from new long-term borrowings | |||
| Cash repayment of existing long-term borrowings | ( | ( | |
| Cash inflow from issue of new ordinary shares | |||
| Cost of share issue paid in cash | 25 | ( | ( |
| Other finance costs paid in cash | | ( | |
| Net cash flows from financing activities | | ||
| Net movement in cash and cash equivalents | | ( | |
| Foreign exchange differences to cash and cash equivalents on consolidation | | ( | |
| Cash and cash equivalents at 1 January | | ||
| Cash and cash equivalents at 31 December |
| 2024 | 2024 | 2023 | 2023 | |
| Closing | Average | Closing | Average | |
| SGD* | n/a | n/a | 1.7188 | 1.6684 |
| EUR | 1.2097 | 1.1789 | 1.1534 | 1.1495 |
| USD | 1.2521 | 1.2786 | 1.2732 | 1.2432 |
| been focused on the development of the IM Platform, the provision of due diligence services, and the facilitation | |
| of the initial IM transactions that have taken place. | |
| The key metrics assessed by the Board of Directors include revenue and adjusted operating profit (before | |
| impairment charges and fair value adjustments) which is presented below. Revenue is presented by basis | |
| of IFRS 15 ("Revenue from Contracts with Customers”) revenue recognition and by service line. | Inventory |
| Monetisation | |
| Year ended 31 December 2024 | £ 000 |
| Revenue | 129 |
| Operating loss from continuing operations before | |
| impairment charges and fair value adjustments | (833) |
| All the Group’s revenue from due diligence fees is recognised at a point in time. Of the revenue generated from | |
| Inventory Monetisation fees, £19,000 is generated from origination fees which is recognised at a point in time, and |
| Inventory | Consolidated Group – | ||
| Monetisation | Head office | continuing operations | |
| Year ended 31 December 2023 | £ 000 | £ 000 | £ 000 |
| Revenue from continuing operations | |||
| Due diligence fees | 94 | - | 94 |
| Inventory Monetisation fees | 64 | - | 64 |
| Revenue from continuing operations | 158 | - | 158 |
Operating loss from continuing operations before impairment charges and fair value adjustments | (1,061) | (2,564) | (3,625) |
| All the Group’s revenue from due diligence fees is recognised at a point in time. Of the revenue generated from |
| Inventory Monetisation fees, £11,000 is generated from origination fees which is recognised at a point in time, and |
the remaining £53,000 is generated from usage of the Group’s IM Platform and services provided by the Group in connection with the IM transaction. This £53,000 of revenue is recognised over time and the amount recognised in the current financial year relates to the performance obligations satisfied prior to 31 December 2023. |
| 2024 | 2023 | |
| £ 000 | £ 000 | |
| Interest expense – long-term borrowings | 47 | 31 |
| Interest expense – related parties | 13 | 7 |
| Other interest expense | 71 | 45 |
| Total finance costs | 131 | 83 |
| 2024 | 2023 | |
| £ 000 | £ 000 | |
| Interest income | 312 | 31 |
| Other operating income | - | 91 |
| Gain arising on settlement of outstanding creditor balance | - | 376 |
| 312 | 498 |
| 2024 | 2023 | |
| £ 000 | £ 000 | |
| Amortisation of internally developed IM platform (note 12) | 5 | 74 |
| Depreciation | 3 | 4 |
| Staff costs (note 8) | 1,631 | 1,850 |
| Professional and legal fees | 625 | 1,551 |
| Contractor costs | 73 | 215 |
| Insurance | 98 | 98 |
| Training and recruitment costs | 7 | 5 |
| Long-term incentive plan costs ("LTIP’s") | 11 | 131 |
| 2024 | 2023 | |
| £ 000 | £ 000 | |
| Impairment charges – intangible assets (note 12) | 48 | 384 |
| Impairment charges – trade and other receivables (note 14) | 270 | - |
| Fair value adjustments on investments (note 27) | 284 | 68 |
| Total impairment charges and Fair value adjustments | 602 | 452 |
| 2024 | 2023 | |
| £ 000 | £ 000 | |
| Amortisation of intangible assets arising on acquisition (note 26)* | - | 442 |
| Foreign currency translation gain reclassified to other comprehensive income (note 26) | - | 62 |
| Profit on disposal of 81% of TradeFlow (note 26) | - | (718) |
| - | (214) |
| 2024 | 2023 | |
| £ 000 | £ 000 | |
| Fees payable to the Company’s auditors for the audit of the consolidated | ||
| financial statements | 121 | 110 |
| Fees payable to the Company’s auditors and its associates for other services | ||
| to the Group: | ||
| Audit of the Companies subsidiaries | 15 | 20 |
| Audit fees relating to prior periods | - | 6 |
| Total audit fees | 136 | 136 |
| Non-audit assurance services | - | - |
| Total audit and non-audit assurance related services | 136 | 136 |
| 2024 | 2023 | |
| £ 000 | £ 000 | |
| Wages, salaries and other short term employee benefits | 1,409 | 1,590 |
| Social security costs | 159 | 190 |
| Post-employment benefits | 63 | 70 |
| Total staff costs | 1,631 | 1,850 |
| 2024 | 2023 | |
| £ 000 | £ 000 | |
| Wages, salaries and other short term employee benefits | - | 337 |
| Social security costs | - | 11 |
| Total staff costs – discontinued operations* | - | 348 |
| 2024 | 2023 | |
| No. | No. | |
| Executive directors | 1 | 2 |
| Finance, Risk and HR | 5 | 4 |
| Sales and marketing | 2 | 3 |
| Legal | - | 1 |
| Operations and Platform development | 7 | 11 |
| Total average number of people employed* | 21 |
| 2024 | 2023 | |
| £ 000 | £ 000 | |
| Wages, salaries and short-term employee benefits | 1,000 | 1,254 |
| Social security costs | 92 | 115 |
| Post-employment benefits | 37 | 44 |
| Total key management compensation | 1,129 | 1,413 |
| 2024 | 2023 | |
| £ 000 | £ 000 | |
| Current Taxation Expense | ||
| UK Corporation tax | (139) | - |
| Foreign taxation paid/(receivable) by subsidiaries – continuing operations | - | - |
| (139) | - |
| 2024 | 2023 | |
| £ 000 | £ 000 | |
| Loss before tax | (3,062) | (4,345) |
| Corporation tax at standard rate – 25.0% (2023: 23.5%) | (766) | (1,022) |
| Effect of expenses not deductible in determining taxable profit (tax loss) | 165 | 82 |
| Increase in tax losses carried forward which were unutilised in the current year | 598 | 912 |
| Tax adjustments in respect of foreign subsidiaries (timing differences) | - | - |
| Over provision of deferred tax in prior years | (139) | - |
| Income not taxable | - | - |
| Deferred tax not recognised | 3 | 28 |
| Differences between UK and foreign tax legislation | - | - |
| Total tax charge | (139) | - |
| 2024 | 2023 | |
| No. | No. | |
| Share warrants - issued | 9,224,804,855 | 9,297,651,062 |
| Share warrants – to be issued | 2,250,000,000 | 2,250,000,000 |
| Long-term incentive plan ("LTIP") options | 228,256,365 | 1,095,753,404 |
| Total | 11,703,061,220 | 12,643,404,466 |
| for the Year Ended 31 December 2024 |
| As at | As at | |
| 31 December 2024 | 31 December 2023 | |
| £ 000 | £ 000 | |
| Trade receivables | 82 | 15 |
| Other receivables | 946 | 976 |
| Prepayments | 60 | 35 |
| Total trade and other receivables | 1,088 | 1,026 |
| As at | As at | |
| 31 December 2024 | 31 December 2023 | |
| £ 000 | £ 000 | |
| Receivable from related party | - | 772 |
| Interest receivable from related party | 7 | 22 |
| Other related party receivable | 45 | 53 |
| Total receivable from related party | 52 | 847 |
| As at 31 December 2024 | As at 31 December 2024 | ||||
| No. 000 | £ 000 | No. 000 | £ 000 | ||
| Equity | |||||
| Ordinary shares of £0.00002 each | 71,732,151 | 1,434 | 61,232,096 | 1,224 | |
| Deferred shares of £0.04000 each | 63,084 | 2,523 | 63,084 | 2,523 | |
2018 | Deferred shares of £0.01000 each | 224,194 | 2,242 | 224,194 | 2,242 |
| Total | 72,019,429 | 6,199 | 61,519,374 | 5,989 |
| As at 31 December 2024 | As at 31 December 2024 | |||
| No. 000 | £ 000 | No. 000 | £ 000 | |
| Ordinary shares as at 1 January | 61,519,374 | 5,989 | 56,908,846 | 5,897 |
| New ordinary shares issued to TAG in connection | ||||
| with the settlement of the TAG Working Capital Facility | 1,500,000 | 30 | - | - |
New ordinary shares issued in connection with the New Equity Subscription Agreement dated 14 May 2024 | 9,000,000 | 180 | - | - |
| New ordinary shares issued to fulfil the conversion | ||||
| of Open Offer warrants | 55 | - | 110,528 | 2 |
| New ordinary shares issued to Venus Capital S.A. | ||||
| in connection with 2023 Venus Subscription | - | - | 4,500,000 | 90 |
| Total at 31 December | 72,019,429 | 6,199 | 61,519,374 | 5,989 |
| As at | As at | |
| 31 December 2024 | 31 December 2023 | |
| £ 000 | £ 000 | |
| Trade payables | 820 | 1,314 |
| Other payables | 1,051 | 943 |
| Current portion of long-term bank borrowings | 210 | 192 |
| Social security and other payroll taxes due | 1,903 | 1,566 |
| Accruals | 415 | 488 |
| Contract liabilities | 75 | 59 |
| Accrued interest payable to related party | - | 7 |
| Total trade and other payables | 4,474 | 4,569 |
| As at | As at | |
| 31 December 2024 | 31 December 2023 | |
| £ 000 | £ 000 | |
| Non-current portion of long-term bank borrowings | 364 | 590 |
| Working capital loan due to TAG | - | 250 |
| Total long-term borrowings | 364 | 840 |
| 18 Provisions | ||
| Post-employment | Provision for risks | |
| benefits | and charges | |
| £ 000 | £ 000 | |
| At 1 January 2023 | 37 | |
| Released to profit and loss | - | (28) |
| Provided for in the year | 17 | 139 |
| Payments | (13) | |
| Actuarial (gain)/loss | 3 | |
| At 31 December 2023 | 44 | 194 |
| Forex retranslation adjustment | (2) | |
| At 1 January 2024 | 42 | 190 |
| Carrying value | Carrying value | Fair value | Fair value | |
| as at | as at | as at | as at | |
| 31 December 2024 | 31 December 2023 | 31 December 2024 | 31 December 2023 | |
| £ 000 | £ 000 | £ 000 | £ 000 | |
| Financial assets at amortised cost: | ||||
| Cash and cash equivalents | 34 | 5 | 34 | 5 |
| Trade receivables | 82 | 15 | 82 | 15 |
| Receivable from related party | 52 | 847 | 52 | 847 |
| Other receivables | 946 | 974 | 946 | 974 |
| 1,114 | 1,841 | 1,114 | 1,841 |
| Carrying value | Carrying value | Fair value | Fair value | |
| as at | as at | as at | as at | |
| 31 December 2024 | 31 December 2023 | 31 December 2024 | 31 December 2023 | |
| £ 000 | £ 000 | £ 000 | £ 000 | |
| Financial liabilities at amortised cost: | ||||
| Long-term borrowings | 574 | 1,032 | 574 | 1,032 |
| Trade payables | 820 | 1,314 | 820 | 1,314 |
| Other payables | 1,051 | 943 | 1,051 | 943 |
| 2,445 | 3,289 | 2,445 | 3,289 |
| Carrying value | Maximum exposure | Carrying value | Maximum exposure | |
| as at | as at | as at | as at | |
| 31 December 2024 | 31 December 2024 | 31 December 2023 | 31 December 2023 | |
| £ 000 | £ 000 | £ 000 | £ 000 | |
| Cash and cash equivalents | 34 | 34 | 5 | 5 |
| Trade receivables | 82 | 82 | 15 | 15 |
| Receivable from related party | 52 | 52 | 847 | 847 |
| 168 | 168 | 867 | 867 |
| As at | As at | |
| 31 December 2024 | 31 December 2023 | |
| £ 000 | £ 000 | |
| Financial assets | ||
| Cash and cash equivalents: Sterling | 1 | 3 |
| Cash: Euro | 33 | 2 |
| Trade receivables: Sterling | - | - |
| Trade receivables: Euro | 82 | 15 |
| Financial liabilities | ||
| Trade payables: Sterling | 478 | 865 |
| Trade payables: Euro | 342 | 449 |
| Long-term borrowings: Sterling | - | 250 |
| Long-term borrowings: Euro | 574 | 782 |
| drawn under the TAG Top-Up Shareholder Loan Agreement. | |||
| Subsequent to the 31 December 2024, the Board entered into the Nuburu On-Demand Facility for US$5,150,000 and | |||
| agreed to release TAG from its outstanding obligations under the TAG Top-Up Shareholder Loan Agreement once the | |||
| full amount under the new facility has been received. Further details of this new funding facility can be found in note | |||
30. This action was taken by the Board due to continued underperformance of TAG a commitments in line with the TAG Top-Up Shareholder Loan Agreement and the rece | |||
| TAG’s financial position, for which further details can be found in note 14. | Between | Between | |
| Up to 3 months | 3 and 12 months | 1 and 2 years | |
| At 31 December 2024 | £ 000 | £ 000 | £ 000 |
| Liabilities | |||
| Long-term borrowings | 44 | 148 | 193 |
> > | |
> | |
| Number of | |||
| warrants | |||
| Date of issue | outstanding | Exercise price | Expiry date |
| 4 January 2022 | 77,763,767 | £0.00174 | 4 January 2025 |
| 2 February 2022 | 79,179,799 | £0.00171 | 2 February 2025 |
| 4 March 2022 | 105,948,198 | £0.00128 | 4 March 2025 |
| 14 July 2022 | 176,149,157 | £0.00085 | 14 July 2025 |
| Total | 439,040,921 |
| Number of | |||
| warrants | |||
| Date of issue | outstanding | Exercise price | Expiry date |
| 1 October 2021 | 443,726,031 | £0.00316 | 1 October 2024 |
| 1 November 2021 | 29,197,856 | £0.00314 | 1 November 2024 |
| 1 December 2021 | 49,867,625 | £0.00184 | 1 December 2024 |
| Total | 522,791,512 |
| Number of | Number of | |
| warrants outstanding | warrants outstanding | |
| at 31 December 2024 | at 31 December 2023 | |
| Share warrants issued to Mercator | 439,040,921 | 961,832,433 |
| Share warrants issued to Venus Capital | 8,175,000,000 | 8,175,000,000 |
| Share warrants to be issued to Venus Capital | 2,250,000,000 | 2,250,000,000 |
| Share warrants issued to retail shareholders | 160,763,933 | 160,818,629 |
| Share warrants issued in connection with New Equity | ||
| Subscription Agreement completed in May 2024 | 450,000,000 | - |
| Total | 11,474,804,854 | 11,547,651,062 |
| 2024 | 2023 | ||
| £ 000 | £ 000 | ||
| Share warrants to be issued to Venus Capital | - | 1,717 | |
| Increase in fair value of outstanding warrants issued to Venus | |||
| Capital and retail shareholders as a result of expiry date extension | - | 346 | |
May 2024 | Subscription Agreement | 52 | - |
| Total | 52 | 2,063 |
| Employee share scheme awards |
| October 2022 Employee share scheme |
| On 31 October 2022, the Group awarded an long term-term incentive plan (“LTIP”) conditional on performance |
| For those share schemes with market related vesting conditions, the fair value is determined using the Monte Carlo |
| model at the grant date. The following table lists the inputs to the model used for the awards granted in the year |
| ended 31 December 2022 based on information at the date of grant: |
| LTIP awards (granted on 31 October 2022) |
| Share price at date of grant |
| Award price |
| Volatility |
| LTIP awards (granted on 31 October 2022) | TSR element additional holding period |
| Share price at date of grant | 0.08 pence |
| Award price | 0.08 pence |
| Volatility | 116.73% |
| Life of holding period | 2 years |
| Risk free rate | 3.60% |
| Dividend yield | 0% |
| Fair value per award with holding period | 0.0208 pence |
| 2024 | 2023 | |
| No. | No. | |
| Outstanding at 1 January | 786,658,094 | 874,783,094 |
| Conditionally awarded in year | - | - |
| Exercised | - | - |
| Forfeited or expired in year | (228,883,759) | (88,125,000) |
| Lapsed at 31 December due to performance condition not being met | (557,774,335) | |
| Outstanding at 31 December | - | 786,658,094 |
| Exercisable at the end of the year | - | - |
24 Share-based payments | |
| LTIP awards (granted on 19 May 2023) | TSR element | Inventory Monetisation element |
| Share price at date of grant | 0.14 pence | 0.14 pence |
| Award price | 0.14 pence | 0.14 pence |
| Volatility | 127.25% | 127.25% |
| Life of award | 2 years | 2 years |
| Risk free rate | 3.87% | 3.87% |
| Dividend yield | 0% | 0% |
| Fair value per award | 0.0924 pence | 0.1165 pence |
| 2024 | 2023 | |
| No. | No. | |
| Outstanding at 1 January | 309,095,310 | - |
| Conditionally awarded in year | - | 343,548,435 |
| Exercised | - | - |
| Forfeited or expired in year | (80,838,945) | (34,453,125) |
| Outstanding at 31 December | 228,256,365 | 309,095,310 |
| Exercisable at the end of the year | - | - |
| 2024 | 2024 | |
| Costs recognised | Costs recognised | |
| in share premium | in retained earnings | |
| £ 000 | £ 000 | |
| Share warrants issued in connection with New Equity Subscription | ||
| Agreement dated May 2024 (note 24) | 52 | - |
| Other costs (legal fees, listing fees, commission cost) | 140 | - |
| Total | 192 | - |
| 2023 | 2023 | ||
| Costs recognised | Costs recognised | ||
| in share premium | in retained earnings | ||
| £ 000 | £ 000 | ||
2023 | Venus Subscription warrant costs (note 24) | 1,717 | - |
| Other costs (legal fees, listing fees, commission cost) | 254 | - | |
| Impact of extension of expiry date of warrants issued during 2022 | |||
| relating to Capital Enhancement plan and Open Offer warrants (note 24) | 132 | 214 | |
| Total | 2,103 | 214 |
26 Loss from discontinued operations recognised in the prior year comparative period |
| 6 months to | |
| 30 June 2023* | |
| £ 000 | |
| Net cash flow from operating activities | (405) |
| Net cash flow from investing activities | - |
| Net cash flow from financing activities | 405 |
| Net cash outflow | - |
| As at | |
| 30 June 2023 | |
| £ 000 | |
| Accounting fair value of the 81% ownership of the TradeFlow operations disposed of by the Group | 2,000 |
| Accounting fair value of 19% ownership of the TradeFlow operations retained by the Group | 352 |
| 2,352 | |
| Less: | |
| Accounting fair value of net assets disposed of by the Group | (1,634) |
| Profit on disposal of 81% of TradeFlow | 718 |
| As at | |
| 30 June 2023* | |
| £ 000 | |
| Assets | |
| Intangible assets | 5,841 |
| Tangible assets | 2 |
| Trade and other receivables | 174 |
| Contract assets | 119 |
| Cash and cash equivalents | 305 |
| Assets of disposal group held for sale | 6,441 |
| Liabilities | |
| Trade and other payables | 482 |
| Long-term borrowings | 3,440 |
| Deferred tax liability | 885 |
| Liabilities of disposal group held for sale | 4,807 |
| Net assets | 1,634 |